Biography/Memoir

…psychedelic activists… after decrim wins

Jag Davies, a drug policy consultant with many years of experience in psychedelic policy at Drug Policy Alliance and MAPS, told Filter that decriminalization of psychedelics is a small step towards ensuring the safety—and legal rights—of people who use drugs in general.  The organizers behind both the Denver and Oakland initiatives have publicly stated that they hope these efforts can…

READ MORE
Biography/Memoir

Prescription opioid overdoses drop, as fentanyl deaths skyrocket

“It’s important that the public and policymakers recognize that the addiction crisis is unfortunately still alive and well. It’s just shifting.” – Adam Leventhal, director of the University of Southern California’s Institute for Addiction Science. Fentanyl, a powerful synthetic opioid often sold as a street drug, surpassed prescription opioids in 2015 as the most lethal overdose…

READ MORE
Biography/Memoir

DEA… a psychedelic plant, and a controversy… at Miami University

“Instead of placing arbitrary restrictions on conservatory holdings, we should be making sure that conservatories are sensibly and knowledgeably curated,” Executive Director of the American Anthropological Assiciation, Ed Liebow said. Since it’s not feasible for every researcher to travel to West Africa, Liebow said the most suitable approach was to establish conservatories where key specimens…

READ MORE
Biography/Memoir

Wuhan [China] signs letter of intent with Biodelta [South Africa] one month after launching psilocybin division

Although the psilocybin industry is still in its nascent stages, all signs suggest that the momentum behind developing psychedelic medicines will continue to grow.  As James Hamblin recently wrote in The Atlantic, “The growth of cannabis is a reminder that once there is money to be made, industries form lobbies in Washington, D.C., and it becomes…

READ MORE
Biography/Memoir

Pushes to make it easier to study [psilocybin-containing] mushrooms and other psychedelic drugs

Legislation [was introduced] on Friday, June 10, 2019 to remove a legal barrier that scientists say makes it unnecessarily difficult for them to study the medical benefits of psychedelic drugs like psilocybin and MDMA. “Academics and scientists report that provisions like this create [stigma] and insurmountable logistical hurdles to researching schedule I drugs,” the summary…

READ MORE